This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days (TQT)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00686179
First received: May 27, 2008
Last updated: September 24, 2008
Last verified: September 2008
  Purpose
The purpose of this study is to evaluate the effects on cardiac repolarisation of supratherapeutic doses of AZD3480 compared to placebo in healthy male volunteers, subgrouped as extensive metabolisers and poor metabolisers according to CYP2D6 metabolic capacity, using moxifloxacin as positive control.

Condition Intervention Phase
Healthy Drug: AZD3480 Drug: Moxifloxacin Drug: PLACEBO Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Double-Blind, Randomised, Multicentre, Placebo-Controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days, Using Moxifloxacin as a Positive Control, in Healthy Male Volunteers, CYP2D6 Extensive and Poor Metabolisers.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • QTcX interval (supratherapeutic doses in comparison to placebo).Subject-specific correction of QT, QTcF and QTcB (supportive outcome variables).Bazett QTcB=QT*RR-1/2Fridericia QTcF=QT'RR-1/3 [ Time Frame: 11 dECG measurements x 4 (4-way crossover) ]

Secondary Outcome Measures:
  • QTcX (therapeutic doses in comparison to placebo).PR-, QRS-, RR-intervals [ Time Frame: 11 dECG measurements x 4 (4-way crossover) ]
  • Plasma concentration (AUC, Cmax, tmax etc) [ Time Frame: 11 PK-measurements x 4 (4-way crossover) ]
  • Registration of AEs, blood pressure, ECG, clinical laboratory tests [ Time Frame: From enrolment to follow-up ]

Enrollment: 75
Study Start Date: January 2008
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Escalating doses of AZD3480 during 6 days
Drug: AZD3480
Capsule, oral, single dose, 6 days
Other Name: TC-1734-226
Experimental: 2
Repeated doses of AZD3480 during 6 days
Drug: AZD3480
Capsule, oral, single dose, 6 days
Other Name: TC-1734-226
Placebo Comparator: 3
Placebo during 6 days
Drug: PLACEBO
Capsule, oral, single dose
Active Comparator: 4
Placebo during 5 days, active day 6
Drug: Moxifloxacin
Capsule(encapsulated), oral, single dose

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participation in a previous study for genotyping for identification to be extensive or poor metaboliser (CYP2D6 enzyme)
  • Physically and mentally healthy male volunteers

Exclusion Criteria:

  • History of clinically significant diseases or illness.
  • Participation in another study the last 3 months
  • Prescribed or non-prescribed medications from 3 weeks prior to first treatment day until follow-up except for paracetamol (max 1.5 g per day.)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00686179

Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Hans-Göran Hårdemark Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden
  More Information

Responsible Party: Hans-Göran Hårdemark, MD, PhD, Medical Science Director, AZD3480, AstraZeneca R&D, Södertälje, Sweden
ClinicalTrials.gov Identifier: NCT00686179     History of Changes
Other Study ID Numbers: D3690C00004
EUdract NO 2007-004859-11
Study First Received: May 27, 2008
Last Updated: September 24, 2008

Keywords provided by AstraZeneca:
TQT
ECG
QT
QTc
AZD3480
ECG(QTc effects)

Additional relevant MeSH terms:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 21, 2017